When a family member falls ill to a deadly disease, your perspective on life changes. When the medical community doesn’t have answers, you seek your own solutions.
Such is the story of TRICCAR Holdings, Inc.
Bill Townsend, a long-time marketing and technology entrepreneur, began his investigations into plant-based medicines for treatment of common diseases and ailments after his sister-in-law, Cynthia, was diagnosed with amyotrophic lateral sclerosis, a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS or Lou Gehrig’s Disease is an almost certain death sentence for its victims and Cynthia was given 2-3 years to live.
Three years into the disease, having exhausted all medically approved options, including the drug riluzole, Eastern medicine, and stem cell treatments, Cynthia was motionless and confined to a wheelchair. She could not speak and had difficulty swallowing. Even simple things like resting or getting a family member’s attention became impossible. Her discomfort from being mentally awake but trapped in a body that no longer responded to her commands resulted in her sleeping approximately 1 hour each night, causing additional health issues.
Based on research we conducted, Cynthia began a daily treatment of 1 capsule nightly of TRICCAR Formula #30. Within one week of beginning treatment, Cynthia’s sleep improved from 1 hour to 8 hours each night, appetite increased, and swallowing became easier.
Within a few months of beginning treatment, she regained much of her swallowing capabilities which delayed the need for a feeding tube. Her pain levels decreased from 6-8 (on a scale of 1 to 10 with the most severe pain) to 0-1.
Today, 7 years after diagnosis, and 4 years past when her doctors said she'd likely pass, she is able to move her hand in order to communicate via phone and computer, and, because of her ability to sleep through the night, her mood has improved, she became healthier looking, has put on weight, and actually looks forward to a time when a cure for ALS may be available.
Her sleep cycle is a consistent 6-8 hours a night plus a 1-2 hour nap in the afternoon and she feels “less fearful” of the debilitating and terminal disease that is ALS.
The benefits of TRICCAR’s formula, along with its cost-effectiveness ($180/month), led Mr. Townsend to begin investigating other natural solutions to the world’s most common diseases.
Continued investigations into ALS led to the development of Formula #70, which in initial tests, has indicated a dramatic reversal of the disease. TRICCAR intends to move this formula into clinical testing and FDA approval as soon as possible.
Realizing there were dozens, if not hundreds, of researchers around the world conducting important investigative studies on nature’s ability to heal, he began recruiting those interested in forging a new path to healthcare—a path that would put patients first, not patents.
A path that would put patients ahead of profits.
A path that would scour the ends of the earth seeking treatments to the world’s most severe diseases and ailments, including ALS, diabetic nerve pain, trigeminal neuralgia, cancer, obesity, hypothyroidism, hypothyroidism, cognitive decline and ADHD.
A path that would incorporate double-blind and clinical studies to prove the effectiveness of nutraceutical supplements and pharmaceutical solutions with one goal in mind:
providing Hope for a Better Tomorrow ™ .
TRICCAR Holdings, Inc. is a for-profit vertically integrated bioceutical company focused on research and product development and commercializing treatments targeting the world’s most devastating diseases and ailments: cancer, hypothyroidism, ALS (Lou Gehrig’s disease), trigeminal neuralgia, diabetic nerve pain, PTSD, cognitive enhancement, ADHD, calcium deficiencies, obesity, and others.
TRICCAR has developed proprietary investigational approaches to disease treatment and abatement. The average success rate for a pharmaceutical company (disease identification-to- product) is 9.6%.2 TRICCAR’s initial 28 months of R&D led to a November 2016 breakthrough in pre-formulation hypothesis-based design and manufacturing procedures that significantly increased success rates from 16.4% to 47.2%. Another advancement increased success rates to 68.4%. This proprietary approach speeds hypothesis-to-testing times, leading to rapid prototyping, and shorter time to double-blind and/or clinical testing and thus, increased speed to market and ROI.
TRICCAR’s business model features a dual-approach that includes bioceuticals (supplements not requiring Food & Drug Administration approval) and FDA-approved pharmaceuticals.
Over $66 million has been invested to date in research, development and double-blind and clinical studies.
We won't ingest something that hasn't been proven to work and we certainly are not going to sell something that is useless. All of TRICCAR’s formulae must pass rigorous quality, safety and efficacy trials including double-blind and/or clinical studies. If at least 85% of participants do not see noticeable results, we abandon the formula and move on to another one. To support of efforts, we purchased and operate our own packaging facility in Mesa, Arizona.
Our hypothesis-driven approach to disease abatement includes alternatives to toxic procedures and drugs that have been shown to kill tissue, cause organ damage, weaken immunity, or otherwise produce side effects that are sometimes worse than the diseases they treat.
TRICCAR’s product pipeline of over 30 treatments and solutions addresses obesity and organ fat reduction, hypothyroidism, congenital toxoplasmosis, cognitive enhancement, ADHD, diabetic nerve pain, cancer, non-melanoma skin cancer, Chronic Traumatic Encephalopathy (CTE), and general wellness support.
Our endocannabinoid support formulae are scheduled to be released soon. They feature the highest percentage by volume full spectrum cannabidiol (CBD) of any product currently on the market. We believe so strongly in the benefits of CBD and terpenes from the hemp plant that we became a charter member of the American Hemp Products Council, a group that petitions Congress to enact truth in labeling and truth in advertising laws for hemp products.
CannaPros, is TRICCAR's wholly-owned division that focuses on endocannabinoid research.
TRICCAR’s research into cannabinoids (CBD) holds promise in supporting the human and animal endocannabinoid systems. The Company has over a dozen formulae based on naturally occurring plant cannabinoids, including plant species that are legal to grow and cultivate in most countries, including the United States, and a proprietary breed of plants which TRICCAR has developed. We are also developing a means to replicate cannabinoids in the lab, potentially eliminating the need to plant thousands of acres of hemp. Initial indication is we can drop the price of CBD from $30 per gram to under 90 cents a gram, greatly increasing affordability of this naturally occurring element.
We develop things that help people and we put our own money to work helping others. The Company earmarks a percentage of profits to our two non-profit entities that provide low-cost supplements to financially disadvantaged patients and ecological support for governments, NGOs, and universities to facilitate reclamation of distressed habitats and teach sound cultivation practices that protect the environment for future generations, providing hope for a better tomorrow.
OFF™ : Possibly the first weight loss bioceutical that requires no change in diet or exercise in order to remove stubborn body fat. Taken first thing in the morning with at least 6 ounces of water (and for severe cases, at night, too) double-blind results show an average weight loss of 23 pounds in 90 days with a 97% success rate. It is proven very effective with patients suffering from obesity or those seeking long-lasting weight loss.
HYP™ : 12% of the global population will suffer from hypothyroidism during their lifetimes. TRICCAR’s hypothyroidism support bioceutical has been shown that with a minimum use of 90 days, sufferers experience the following results: 81% of subjects experience a reduction in pain, 79% increased energy, 68% get relief from constipation, 52% obtain relief from sensitivity to cold, 66% report improved sexual performance, and 39% experienced weight loss.
MND™ : A cognitive improvement formula made from a proprietary blend of plant extracts. Testing to date on subjects aged 45-78 shows an average self-reported increase in memory and cognition of 67% after 90 days use. TRICCAR is planning a large scale double-blind study to validate these results.
FCS™ : Created as an offshoot of our memory formula, TRICCAR's FCS formula is designed for students, ages 12-25, to enhance focus for studies or for athletics seeking mental sharpness. Independent analysis of the product and of competent and reliable scientific evidence supports the following:
a) Improves and boosts energy,
b) Improves alertness, focus, and concentration,
c) Supports the formation of short-term memory and the consolidation of long-term memory, sustains mitochondrial biogenesis and neuroprotection,
d) Supports brain health, cholinergic tone and neurotransmission, human cognitive functioning, plus the formation of short-term memory, and the consolidation of long-term memory,
e) Supports the ability to create new memories and retrieve memories, and
f) Supports the ability to learn, recall information, focus attention on attention-demanding tasks, reason, problem solving, and safely supports cognitive functioning.
BPB™ : This blood performance boost formula aids in red blood cells separating: allowing white blood cells freedom of movement and increased ability to destroy harmful bacteria. It's a great bioceutical to ensure our blood is performing at its best.
CBX™ & CBZ™ : These softgels provide the highest level of bioavailable cannabidiols (CBD) of any product we've tested. The morning formula works to support your endocannabinoid system and nighttime formula adds gentle sleep aids so you get great rest while you heal.
TRICCAR has conducted limited testing on a trigeminal neuralgia formula. For those suffering from this dreadful nerve disease--often called the Suicide Disease because of its ranking as the most painful disease known to mankind--our formula shows promise in being the only treatment for TN1 and TN2 that provides long-term relief.
Our approach to treating diabetic nerve pain is equally exciting with our formula showing promise in treating the common symptoms of diabetes. Diabetic neuropathy can cause numbness or tingling in your fingers, toes, hands, and feet. Another symptom is a burning, sharp, or aching pain (diabetic nerve pain). Popular treatments include Lyrica, Gabarone, Neurontin, Carbatrol, Tegretol, or anti-depressants. Our Formula #54 appears to greatly eliminate numbness, tingling, and pain. Full scale clinical studies are being planned.
We have increased the number of formulae that may be utilized to treat multiple cancers. Of personal interest to Mr. Townsend is a formula for pancreatic cancer which took the life of his former business partner, Hollywood director James Kellahin, as well as actor Patrick Swayze and tech legend Steve Jobs. The Company plans to begin clinical trials after its cultivation and research facility is fully operational and consistent extraction of key ingredients is possible. These pharmaceutical solutions may require FDA approval before being made available to the public and the Company intends to partner with leading pharmaceutical firms to bring these promising treatments to market.
Sign up to receive updates, news, and more.
All statements and expressions are the sole opinion of the editor and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
The statements made within the pages of this website are those of the author and should not be taken to mean that any product discussed herein has been proven to be effective for any claims stated herein.
TRICCAR Holdings, Inc. is a privately-held corporation. All inquiries should be addressed to legal @ triccar.com.
Wishing you good health.
Copyright © 2018 TRICCAR Holdings, Inc. - All Rights Reserved.
No part of this site may be reproduced without written permission.
Note about information contained on this website: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.